Icatibant Zentiva (Icatibant Acetate)

Icatibant acetate works by competitively binding to the bradykinin B2 receptor, preventing bradykinin from triggering vasodilation and increased vascular permeability. This blockade stops the cascade that leads to swelling in hereditary angioedema.

The prescribed dose of Icatibant Zentiva is determined by the treating physician based on the patient’s condition and clinical response. The product is supplied as a 30 mg/1 mL subcutaneous injection.

Safety of icatibant acetate in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other options such as C1‑inhibitor concentrates replace the deficient protein. Icatibant offers a rapid, subcutaneous route and does not require plasma‑derived products, but the choice depends on individual patient factors and physician preference.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep it in the original packaging until use to maintain stability.

Icatibant Zentiva is given as a single subcutaneous injection into the abdomen or thigh. The injection is performed by a healthcare professional or trained patient following aseptic technique.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, thrombocytopenia, and rare cases of life‑threatening angioedema unrelated to hereditary angioedema. Immediate medical attention is required if any of these occur.

Patients with known hypersensitivity to icatibant acetate or any component of the formulation should not use the product. Caution is also advised for individuals on ACE inhibitors or with uncontrolled cardiovascular conditions.